chufangao/CTO huggingface dataset:
Clinical trial NCT01566721: A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Official title: A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer
Acronym: SafeHER
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 2577.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-05-17
Primary completion date: 2015-03-10
Completion date: 2020-02-19
Baseline population: Intent-to-Treat (ITT) Population: All participants enrolled into the study regardless of whether treatment was received.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04654143: Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BVL-GSK098 in Healthy Volunteers
Official title: A Phase I, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics and Food Effect of BVL-GSK098 Administered as Single and Multiple Oral Doses to Healthy Volunteers
Sponsor: BioVersys AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-02
Primary completion date: 2022-05-30
Completion date: 2023-01-16
Plan to share individual participant data: NO
Clinical trial NCT02736318: OD-PHOENIX in Talus Osteochondral Lesion
Official title: Treatment of Osteochondral Lesion of Talus With Processed Osteochondral Allograft
Acronym: TBF3
Sponsor: TBF Genie Tissulaire (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Low accrual rate
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-01-27
Primary completion date: 2021-09-07
Completion date: 2021-09-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04377087: Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
Official title: Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-29
Primary completion date: 2023-05-31
Completion date: 2023-05-31
Baseline population: All enrolled participants
Plan to share individual participant data: NO
Clinical trial NCT06102213: Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
Official title: A Randomized, Open-Label, Multicenter, Phase 2a Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Sponsor: Prolacta Bioscience (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor business decision to terminate the study early
Enrollment: 46.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-09-18
Primary completion date: 2024-08-12
Completion date: 2024-08-12
Plan to share individual participant data: YES
IPD sharing description: To be determined
IPD time frame: To be determined
IPD access criteria: To be determined
Clinical trial NCT03615105: Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Official title: Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-25
Primary completion date: 2024-03-06
Completion date: 2024-03-06
Clinical trial NCT05180422: A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Official title: A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis.
Sponsor: Criterium, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Lack of enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-15
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Plan to share individual participant data: NO
Clinical trial NCT03331445: Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Official title: An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections
Sponsor: Nitric Solutions Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Covid Incidence too low and Funding Completed
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-24
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT02587871: Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
Official title: HLA-Mismatched Allogeneic Cellular Therapy (Microtransplantation) After Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia &lt; 60 Years
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI decided not to pursue study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-12
Primary completion date: 2020-11-12
Completion date: 2022-11-12
Clinical trial NCT02362997: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Official title: A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 82.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-04-30
Primary completion date: 2021-10-26
Completion date: 2023-06-30
Clinical trial NCT03422653: A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension
Sponsor: Cara Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 378.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-20
Primary completion date: 2019-04-06
Completion date: 2020-03-26
Plan to share individual participant data: NO
Clinical trial NCT03946891: Nebulized Furosemide in Premature Infants With Bronchopulmonary Dysplasia - A Cross Over Pilot Study of Its Efficacy and Safety
Official title: Nebulized Furosemide in Premature Infants With Bronchopulmonary Dysplasia - A Cross Over Pilot Study of Its Efficacy and Safety
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: The study was stopped due to lack of study staff and inability to enroll subjects into the study due to restrictive inclusion criteria.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Clinical trial NCT03414450: Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
Official title: A Phase 1A Dose Escalation and Phase 1B Expansion Study to Evaluate the Safety and Tolerability of ETC-1907206 in Combination With Dasatinib in Advanced Haematologic Malignancies
Sponsor: EDDC (Experimental Drug Development Centre), A*STAR Research Entities (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Withdrawal requested by D3
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-25
Primary completion date: 2022-02-28
Completion date: 2023-02-28
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03416179: A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Official title: A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA
Acronym: BRIGHT AML1019
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 730.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-04-20
Primary completion date: 2020-06-05
Completion date: 2022-01-17
Baseline population: Full analysis (FA) set included all randomized participants.
Limitations and caveats: In this study, inadvertently a participant was counted twice for an non-SAE Pyrexia at PCD, at SCD update this duplicity has been rectified. Due to this reason total number of participants affected by non-SAE in non-intensive placebo arm was updated to 148.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03602781: Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
Official title: Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Withdrawal Study of Pulmonary Arterial Hypertension(PAH) Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric Oxide (INO)
Sponsor: Bellerophon (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Decision not to proceed with Study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-31
Primary completion date: 2019-06-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT02583269: Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Official title: Phase I Study of Muscadine Grape Extract (MGE) in Advanced Malignancy
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-03-31
Primary completion date: 2017-12-19
Completion date: 2023-04-24
Clinical trial NCT03929497: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
Official title: Interventional, Open-label, Flexible-dose, Long-term Safety Extension Study of Lu AF11167 in Patients With Schizophrenia
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy based on the interim analysis in the 17972A study
Enrollment: 96.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-22
Primary completion date: 2020-09-01
Completion date: 2020-09-14
Clinical trial NCT03241719: Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA
Official title: Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in Vascularized Composite Allotransplantation
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: No participants are currently receiving therapy under this protocol, funding is coming to an end and the PI is leaving the institution.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-17
Primary completion date: 2021-07-21
Completion date: 2021-07-21
Plan to share individual participant data: NO
Clinical trial NCT04377659: Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Official title: A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Based on two large, multicenter, randomized trials showed no benefit to tocilizumab in this setting and study has been closed.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2022-10-28
Completion date: 2022-10-28
Plan to share individual participant data: YES
IPD sharing description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Clinical trial NCT04739709: Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
Official title: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery
Sponsor: Formosa Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 378.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-11
Primary completion date: 2022-03-17
Completion date: 2022-03-17
Baseline population: Intent-to-Treat Population
Clinical trial NCT03499483: Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)
Official title: A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1
Sponsor: Fenway Community Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-24
Primary completion date: 2020-03-30
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT04452669: VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
Official title: Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation
Acronym: VPCOVID
Sponsor: Aerogen Pharma Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-15
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Clinical trial NCT04058132: Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military
Official title: Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel
Sponsor: Uniformed Services University of the Health Sciences (FED)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: funding ran out after unanticipated length of time ( for IRB approval, CRADA, and start letter
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-09
Primary completion date: 2020-03-01
Completion date: 2020-03-01
Plan to share individual participant data: NO
IPD sharing description: none collected
Clinical trial NCT02376699: Safety Study of SEA-CD40 in Cancer Patients
Official title: A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Sponsor: Seagen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study closed due to portfolio prioritization
Enrollment: 159.0 (ACTUAL)
Number of arms: 6.0
Start date: 2015-02-28
Primary completion date: 2023-03-06
Completion date: 2023-04-14
Clinical trial NCT04334967: Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
Official title: Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment
Sponsor: Providence Health & Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: suspected unfavorable risk/benefit assessment
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-30
Primary completion date: 2021-05-27
Completion date: 2022-05-27
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03524118: Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
Official title: A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 183.0 (ACTUAL)
Number of arms: 8.0
Start date: 2018-09-20
Primary completion date: 2022-09-14
Completion date: 2022-09-14
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05932667: Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
Official title: Milademetan and Fulvestrant in GATA3-mutant, ER-positive, HER2-negative Advanced or Metastatic Breast Cancer Patients: a Multicenter Phase II Trial
Acronym: DEMETER
Sponsor: Institut Curie (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Financial partner providing study drug could no longer support the trial
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-10-12
Primary completion date: 2023-11-24
Completion date: 2023-11-30
Plan to share individual participant data: YES
IPD sharing description: Investigators will share de-identified data sets documents generated under the project will be disseminated in accordance with Institut Curie policies.
IPD time frame: Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.
IPD access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
Clinical trial NCT03639415: Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain
Official title: Phase II Study of Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain
Sponsor: Fujian Cancer Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: There is no fund to support
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-30
Primary completion date: 2020-10-30
Completion date: 2021-03-30
Plan to share individual participant data: NO
Clinical trial NCT04800627: Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
Official title: A Phase I/II Trial of Pevonedistat in Combination With Pembrolizumab in Patients With dMMR/MSI-H Cancers
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Per PI
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-29
Primary completion date: 2022-11-03
Completion date: 2022-11-03
Limitations and caveats: Company stopped development of the drug and shut down the entire program with pevonedistat. Takeda had a negative phase III of the agent in liquid tumors and thus shut the program. It was not due to any toxicity, but lack of path for FDA indication.
Clinical trial NCT04270877: Fibromyalgia and Naltrexone: The FINAL Study
Official title: Fibromyalgia and Naltrexone: The FINAL Study
Acronym: FINAL
Sponsor: Odense University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 99.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-06
Primary completion date: 2022-12-27
Completion date: 2022-12-27
Plan to share individual participant data: NO
Clinical trial NCT04377568: Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
Official title: A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
Acronym: CONCOR-KIDS
Sponsor: The Hospital for Sick Children (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: no enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-07
Primary completion date: 2021-12-01
Completion date: 2022-05-01
Clinical trial NCT03238534: Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS
Official title: Relief of Heartburn and Epigastric Pain Comparing Neobianacid® With Omeprazole: a Randomized, Double Blind, Double Dummy, Reference Product Controlled, Parallel Group, Non-inferiority Clinical Study
Sponsor: Aboca Spa Societa' Agricola (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 275.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-12
Primary completion date: 2021-09-03
Completion date: 2021-09-03
Plan to share individual participant data: NO
Clinical trial NCT03723824: Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
Official title: An Open-label, Cohort Study of Grazoprevir/Elbasvir Combination Therapy for Patients With Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
Sponsor: Taichung Veterans General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COV-19 pandemic
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-14
Primary completion date: 2020-11-30
Completion date: 2021-03-13
Plan to share individual participant data: NO